Anu Osinusi
Overview
Explore the profile of Anu Osinusi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
6012
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Jacobson I, Bourgeois S, Mathurin P, Thuluvath P, Ryder S, Gerken G, et al.
J Viral Hepat
. 2023 Feb;
30(5):448-454.
PMID: 36740893
To evaluate the safety and tolerability of the fixed-dose, single-tablet regimen sofosbuvir/velpatasvir (SOF/VEL) for the treatment of hepatitis C virus (HCV) infection in three Phase 3 studies in patients with...
12.
Pan D, Odorizzi P, Schoenichen A, Abdelghany M, Chen S, Osinusi A, et al.
Commun Med (Lond)
. 2023 Jan;
3(1):2.
PMID: 36596885
Background: Remdesivir (RDV) is an intravenous antiviral with activity against SARS-CoV-2 for treatment of hospitalized COVID-19 patients with moderate-to-severe disease. Biomarkers associated with clinical outcomes have been identified for COVID-19,...
13.
Shiha G, Soliman R, Mikhail N, Carrat F, Azzi J, Nathalie G, et al.
J Viral Hepat
. 2022 Jun;
29(9):807-816.
PMID: 35657138
We have recently demonstrated the ability of a simple predictive model (GES) score to determine the risk of hepatocellular carcinoma (HCC) after using direct-acting antivirals. However, our results were restricted...
14.
Gottlieb R, Vaca C, Paredes R, Mera J, Webb B, Perez G, et al.
N Engl J Med
. 2021 Dec;
386(4):305-315.
PMID: 34937145
Background: Remdesivir improves clinical outcomes in patients hospitalized with moderate-to-severe coronavirus disease 2019 (Covid-19). Whether the use of remdesivir in symptomatic, nonhospitalized patients with Covid-19 who are at high risk...
15.
Chuang W, Hu T, Buggisch P, Moreno C, Su W, Biancone L, et al.
Am J Gastroenterol
. 2021 Sep;
116(9):1924-1928.
PMID: 34465694
Introduction: We evaluated 8, 12, or 24 weeks of ledipasvir/sofosbuvir in patients with hepatitis C virus and end-stage renal disease undergoing dialysis. Methods: Primary efficacy end point was sustained virologic...
16.
Murakami E, Bilello J, Li R, Li L, Porter D, Humeniuk R, et al.
Antimicrob Agents Chemother
. 2021 Aug;
65(10):e0139421.
PMID: 34370585
No abstract available.
17.
Goldman D, Aldrich M, Hagmann S, Bamford A, Camacho-Gonzalez A, Lapadula G, et al.
Pediatrics
. 2021 Apr;
147(5).
PMID: 33883243
Objectives: Remdesivir shortens time to recovery in adults with severe coronavirus disease 2019 (COVID-19), but its efficacy and safety in children are unknown. We describe outcomes in children with severe...
18.
Humeniuk R, Mathias A, Kirby B, Lutz J, Cao H, Osinusi A, et al.
Clin Pharmacokinet
. 2021 Mar;
60(5):569-583.
PMID: 33782830
Remdesivir (RDV, Veklury) is a once-daily, nucleoside ribonucleic acid polymerase inhibitor of severe acute respiratory syndrome coronavirus 2 replication. Remdesivir has been granted approvals in several countries for use in...
19.
Isakov V, Gankina N, Morozov V, Kersey K, Lu S, Osinusi A, et al.
Clin Drug Investig
. 2021 Feb;
41(3):291.
PMID: 33620684
No abstract available.
20.
Goldman J, Osinusi A, Marty F
N Engl J Med
. 2020 Nov;
383(25):2486-2487.
PMID: 33156580
No abstract available.